MedTrace Logo

Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

NCT04676867 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 227

Last updated 2022-12-07

Study results available
· View outcomes & findings →

Summary

This study is a placebo-controlled, Phase 2a proof-of-concept clinical study which will evaluate efficacy and safety of dalcetrapib in outpatients patients with mild to moderate, symptomatic, confirmed COVID 19.

Conditions

  • Covid19

Interventions

DRUG

Dalcetrapib

Dalcetrapib 300 mg Film-Coated Tablets

OTHER

Placebo

Placebo Tablets

Sponsors & Collaborators

  • The Montreal Health Innovations Coordinating Center (MHICC)

    collaborator OTHER

  • Covance

    collaborator INDUSTRY

  • DalCor Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • David Kallend · DalCor Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-11
Primary Completion
2021-05-17
Completion
2021-05-17
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04676867 on ClinicalTrials.gov